CG Oncology (CGON) Goodwill & Intangibles (2025 - 2026)
CG Oncology's (CGON) quarterly Goodwill & Intangibles came in at $10.9 million in Q1 2026, little changed on a QoQ basis from $10.9 million in Q4 2025.
Powered by 
Analysis
CG Oncology (CGON) Goodwill & Intangibles (2025 - 2026) Analysis & Trends
CG Oncology (CGON) has 2 years of Goodwill & Intangibles data on file, last reported at $10.9 million in Q1 2026.
- Quarterly Goodwill & Intangibles changed N/A year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (changed N/A YoY) and the FY2025 annual result came in at $10.9 million, changed N/A from the prior year.
- Goodwill & Intangibles was little changed at $10.9 million in Q1 2026, from $10.9 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $14.5 million in Q3 2025 to a low of $10.9 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | CG Oncology | 6.56 Bn | 6.56 Bn | -2.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.84 Mn |
| Mar 31, 2026 | 10.86 Mn |
| Dec 31, 2025 | 10.87 Mn |
| Sep 30, 2025 | 14.51 Mn |